Cite
Osimertinib and Capmatinib Combination Therapy to Overcome MET Y1003N-Mediated Resistance in EGFR-Mutant NSCLC: A Case Report
MLA
Molly Wilgucki, Do, et al. “Osimertinib and Capmatinib Combination Therapy to Overcome MET Y1003N-Mediated Resistance in EGFR-Mutant NSCLC: A Case Report.” JTO Clinical and Research Reports, vol. 3, no. 10, Oct. 2022. EBSCOhost, https://doi.org/10.1016/j.jtocrr.2022.100396.
APA
Molly Wilgucki, D., Vincent Yeung, M., Grace Ho, M., Gabriela L. Bravo Montenegro, M., Greg Jones, Joshua E. Reuss, M., Stephen V. Liu, M., & Chul Kim, M. M. (2022). Osimertinib and Capmatinib Combination Therapy to Overcome MET Y1003N-Mediated Resistance in EGFR-Mutant NSCLC: A Case Report. JTO Clinical and Research Reports, 3(10). https://doi.org/10.1016/j.jtocrr.2022.100396
Chicago
Molly Wilgucki, Do, Md Vincent Yeung, Md Grace Ho, Md Gabriela L. Bravo Montenegro, Greg Jones, Md Joshua E. Reuss, Md Stephen V. Liu, and Md, Mph Chul Kim. 2022. “Osimertinib and Capmatinib Combination Therapy to Overcome MET Y1003N-Mediated Resistance in EGFR-Mutant NSCLC: A Case Report.” JTO Clinical and Research Reports 3 (10). doi:10.1016/j.jtocrr.2022.100396.